Qiagen Nv Stock Today
| QGEN Stock | USD 43.75 0.51 1.18% |
Performance0 of 100
| Odds Of DistressLess than 1
|
Qiagen NV is selling at 43.75 as of the 28th of November 2024; that is 1.18 percent up since the beginning of the trading day. The stock's open price was 43.24. Qiagen NV has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Note, on April 3, 2020, Representative Peter Welch of US Congress acquired under $15k worth of Qiagen NV's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of June 1996 | Category Healthcare | Classification Health Care |
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company was founded in 1986 and is headquartered in Venlo, the Netherlands. Qiagen NV operates under Diagnostics Research classification in the United States and is traded on New York Stock Exchange. The company has 222.26 M outstanding shares of which 3.57 M shares are at this time shorted by private and institutional investors with about 3.88 trading days to cover. More on Qiagen NV
Moving together with Qiagen Stock
| 0.67 | A | Agilent Technologies | PairCorr |
| 0.65 | VALN | Valneva SE ADR | PairCorr |
| 0.72 | ERNA | Eterna Therapeutics | PairCorr |
Moving against Qiagen Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Qiagen Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Thierry Bernard | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | ESG Investing (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, ESG Investing, Health Care, Life Sciences Tools & Services, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Excise Tax Activities | Animal Testing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsQiagen NV can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Qiagen NV's financial leverage. It provides some insight into what part of Qiagen NV's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Qiagen NV (QGEN) is traded on New York Stock Exchange in USA. It is located in Hulsterweg 82, Venlo, Netherlands, 5912 PL and employs 5,800 people. Qiagen NV is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 9.61 B. Qiagen NV conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 222.26 M outstanding shares of which 3.57 M shares are at this time shorted by private and institutional investors with about 3.88 trading days to cover.
Qiagen NV currently holds about 1.89 B in cash with 459.45 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.31.
Check Qiagen NV Probability Of Bankruptcy
Ownership AllocationQiagen NV owns a total of 222.26 Million outstanding shares. The majority of Qiagen NV outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Qiagen NV to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Qiagen NV. Please pay attention to any change in the institutional holdings of Qiagen NV as this could imply that something significant has changed or is about to change at the company. On April 3, 2020, Representative Peter Welch of US Congress acquired under $15k worth of Qiagen NV's common stock.
Check Qiagen Ownership Details
Qiagen Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Dekabank Deutsche Girozentrale | 2024-06-30 | 3.2 M | |
| Millennium Management Llc | 2024-06-30 | 3 M | |
| Victory Capital Management Inc. | 2024-09-30 | 2.6 M | |
| Bnp Paribas Arbitrage, Sa | 2024-06-30 | 2.5 M | |
| Capital Research & Mgmt Co - Division 3 | 2024-09-30 | 2.4 M | |
| State Street Corp | 2024-06-30 | 2.3 M | |
| Legal & General Group Plc | 2024-06-30 | 2.2 M | |
| Citadel Advisors Llc | 2024-09-30 | 2.1 M | |
| Deutsche Bank Ag | 2024-06-30 | 2.1 M | |
| Massachusetts Financial Services Company | 2024-09-30 | 23.1 M | |
| Wellington Management Company Llp | 2024-06-30 | 12 M |
Qiagen NV Historical Income Statement
Qiagen Stock Against Markets
Qiagen NV Corporate Management
| John Gilardi | VP of Corporate Communications and Investor Relations | Profile | |
| Stephane Bancel | Independent Member of the Supervisory Board | Profile | |
| Fernando Beils | Senior Area | Profile | |
| JeanPascal Viola | Senior Development | Profile | |
| Elaine Mardis | Independent Member of the Supervisory Board | Profile | |
| Thomas Ebeling | Independent Member of the Supervisory Board | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Qiagen NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Qiagen Stock, please use our How to Invest in Qiagen NV guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Qiagen NV. If investors know Qiagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Qiagen NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.255 | Earnings Share 0.45 | Revenue Per Share 8.841 | Quarterly Revenue Growth 0.055 | Return On Assets 0.0484 |
The market value of Qiagen NV is measured differently than its book value, which is the value of Qiagen that is recorded on the company's balance sheet. Investors also form their own opinion of Qiagen NV's value that differs from its market value or its book value, called intrinsic value, which is Qiagen NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Qiagen NV's market value can be influenced by many factors that don't directly affect Qiagen NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Qiagen NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if Qiagen NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Qiagen NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.